NCT00192257View on ClinicalTrials.gov

Trial to Compare the Safety, Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus in Children With Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

2,229

Participants

Timeline

Start Date

October 31, 2002

Study Completion Date

May 31, 2003

Conditions
Asthma
Interventions
BIOLOGICAL

CAIV-T and TIV

Trial Locations (2)

Unknown

Berchem

Brussels

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

MedImmune LLC

INDUSTRY

NCT00192257 - Trial to Compare the Safety, Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus in Children With Asthma | Biotech Hunter | Biotech Hunter